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Introduction: Regulatory T cells (Tregs) can play a key role in
suppressing T-cell-mediated immunity in patients with cancer. In this
study, the immune cell composition of the lung tissue and draining lymph
nodes from patients with non-small cell lung cancer was analyzed.
Methods: Samples (solid tumor, tumor border, and tumor-free lung
tissue, as well as intrapulmonal N1 and mediastinal N2 lymph
nodes) from 30 patients subjected to curative resection were ana-
lyzed by immunohistochemistry and flow cytometry.
Results: Immunohistochemistry showed the presence of Foxp3
Tregs in tumor-infiltrated lung tissue, scattered Tregs in tumor-free
lung samples, and a large number of these cells in metastatic lymph
nodes. Using flow cytometry, we observed a significant enhancement
of CD4 T cells and Foxp3 Tregs in the tumor center of adenocar-
cinoma samples, when compared with tumor-free lung tissues and
tumor periphery. This enrichment was associated with a drastic de-
crease in natural killer cell amounts. Metastatic lymph nodes also
showed higher Treg numbers than tumor-free ones in patients with lung
adenocarcinomas. In contrast, patients with squamous cell carcinomas
displayed less profound accumulation of Tregs.
Conclusion: Accumulation of Tregs in the center of lung tumors
and in metastatic lymph nodes in combination with a decrease in the
natural killer cell numbers suggests a critical role of Treg in the
formation of immunosuppressive tumor microenvironment. There-
fore, lung cancer immunotherapy may be improved by a specific
Treg elimination or suppression.
Key Words: Foxp3 Tregs, NK-cells, Lung cancer, Lymph nodes,
Tumor microenvironment.
(J Thorac Oncol. 2011;6: 432–438)
Lung cancer is the leading cause of cancer death worldwide,with a growing incidence in both developed and develop-
ing countries. Because the prognosis remains poor when
using conventional cancer therapy methods, the need for new,
effective adjuvant therapies is apparent.1 Immunotherapy, in
particular an activation of tumor-infiltrating immune cells,
may offer a promising approach. Nevertheless, the success of
such treatment has been limited up to now, probably due to
the suppressive nature of the tumor. Indeed, most patients
with cancer are not able to develop a satisfactory antitumor
immune response, which implies the existence of effective
tumor-specific immune evasion strategies, including the in-
duction of tumor antigen-specific T-cell tolerance.2 Regula-
tory T cells (Tregs) have attracted much interest, due to their
crucial role in the suppression of self-antigen response.2,3 On
the other hand, lung tissue is known to harbor considerable
numbers of natural killer (NK) cells, which are an important
subset of antitumor effector cells.4 Foxp3 has been reported
as a key regulatory gene for the development and function of
Tregs and is a commonly used marker of these cells.5 In
several solid cancers, elevated Treg proportions have been
found in tumor tissue and peripheral blood; increased Treg
numbers were also reported in tumor-infiltrated lymph nodes
(TIL) in melanoma and gastrointestinal tumors.6–9
The aim of this study was to investigate proportions of
Tregs and NK cells in primary lung tumors and in corre-
sponding metastatic lymph nodes of the same patient in
comparison with normal adjacent lung tissue. We showed a
significant enhancement of Treg numbers in tumor tissue and
metastatic lymph nodes. This Treg enrichment was associated
with a drastic decrease in NK cells in tumor tissue. Our
results suggest an important role of Treg in creating an
immunosuppressive tumor microenvironment.
MATERIALS AND METHODS
Patients
A total of 30 patients (men: n  21, women: n  9;
mean age: 63 years) receiving curative resection of non-small
cell lung cancer (NSCLC) (adenocarcinoma: n  16; squa-
mous cell carcinoma: n  14) were enrolled in this study;
none was subjected to preoperative chemotherapy and/or
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radiotherapy. All patients underwent anterolateral thoracot-
omy, entering in the fourth or fifth intercostal space; lobec-
tomy was performed in 17 patients, bilobectomy in three
patients, and pneumonectomy in a total of 10 patients. Rad-
ical mediastinal and hilar lymphadenectomy was realized
concurrently with all procedures, including four compart-
ments in the right-sided thoracotomy (paratracheal, infracari-
nal, inferior mediastinal, and hilar) and four compartments in
the left-sided thoracotomy (aortic, infracarinal, inferior me-
diastinal, and hilar).10,11 The postoperative pathologic stage
for lung cancer was determined according to the 7th edition
of the classification of malignant tumors (TNM), revised in
2009.12 The Ethics Committee of the University of Heidel-
berg approved this study (Study No. 270/2001). Each patient
was informed comprehensively; written consent was given
before participation. A synopsis of the clinical data is pre-
sented in Table 1.
Processing of Tissue Specimens
Immediately after surgical lung resection, tissue sam-
ples were extracted from three different locations. Tumor
tissue was taken from a central area of solid tumor tissue
lacking massive necrosis (tumor center). Tumor border in-
cluded tissue closely adjacent and neighboring the tumor. For
representative tumor-free lung tissue samples, tissue was
taken from the surgically removed lung in the farthermost
position to the tumor (healthy lung).
In 20 patients, lymph node tissue was taken from three
locations: (i) an intrapulmonal lymph node (N1 location) in a
tumor-draining position closest to the tumor, (ii) a mediasti-
nal lymph node (N2 location) in a typical tumor-draining
position (e.g., right upper mediastinal position in a right
upper lobe tumor), and (iii) a mediastinal lymph node (N2
location) in a nontumor draining position (e.g., right lower
mediastinal position in a right upper lobe tumor).
Immunohistochemistry
For routine histopathologic analysis, lung and lymph
node tissues were embedded in paraffin and further processed
for routine hematoxylin and eosin staining. Immunohisto-
chemistry was performed to detect the localization of the
FoxP3 lymphocytes in tumor, lung, and lymph node sam-
ples. Additional sections (1 m thick) were cut, deparaf-
finized, and stained with mouse monoclonal antibodies
(mAbs) against human Foxp3 (eBioscience) and CD4 (Di-
anova) using an autostaining device (Autostainer; DAKO,
Glostrup, Denmark). Assays were performed according to the
manufacturer’s instructions. Immunohistochemical stainings
were analyzed by two experienced pathologists (P.A.S. and
A.W.).
Flow Cytometry
Biopsies of lung tissue and lymph node tissue were
immediately transferred into serum-free Roswell Park Me-
morial Institute (RPMI) culture medium and stored on ice.
After removal of necrotic tissue and fat, biopsies were cut
into small pieces and filtered through a 100-m nylon mesh.
Samples were depleted of red blood cells by ammonium
chloride lysis, washed twice with phosphate-buffered saline,
and used for flow cytometry (FACS).
Single-cell suspensions were stained with directly con-
jugated mouse mAbs against human CD45-PerCP-Cy5.5,
CD3-PerCP-Cy5.5, CD4-FITC, CD8 PE-Cy7, CD25 APC-
FIGURE 1. Regulatory T cell (Treg)-infiltrate primary tumors
(A) and metastatic lymph nodes (B) in patients with lung
cancer. Consecutive paraffin sections of 1 m thickness were
stained with Foxp3 (brown) monoclonal antibodies (mAbs)
and counterstained with hemalaun.
TABLE 1. Summary of the Clinical Data
Histopathology
pT pN Stage
T1 T2 T3 T4 N0 N1 N2 1 2 3A 3B
Squamous cell carcinoma 1 8 2 3 5 6 3 3 4 5 2
Adenocarcinoma 1 13 1 1 5 2 9 5 2 8 1
Total 2 21 3 4 10 8 12 8 6 13 3
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 Regulatory T Cells in Non-small Cell Lung Cancer
Copyright © 2011 by the International Association for the Study of Lung Cancer 433
H7, and CD56-PE or isotype-matched control mAbs (all from
BD Bioscience, Franklin Lakes, NJ), fixed, and permeabil-
ized (eBioscience) according to the manufacturer’s protocol,
followed by staining with Foxp3-APC (eBioscience, San
Diego, CA). Acquisition was performed by four- or five-color
flow cytometry using a FACS Canto II with FACSDiva
software (BD Biosciences) with dead cell exclusion based on
scatter profile. FlowJo software (Tree Star, Ashland, OR) was
used to analyze at least 100,000 events. Data were expressed
as dot plots.
RESULTS
Foxp3 Lymphocytes Infiltrate Primary Lung
Tumors and Metastatic Lymph Nodes
Using immunohistochemistry, both peritumoral infil-
tration and intratumoral infiltration of FoxP3 lymphocytes
into tumor stroma and within agglomerates of tumor cells
were evident (Figure 1A). In addition, scattered Foxp3
lymphocytes were found in the tumor-free lung parenchyma,
often in association or even inside blood vessels. Metastatic
lymph nodes also contained a large number of Foxp3
lymphocytes, more prominent around than within tumor me-
tastases itself (Figure 1B).
CD4CD25Foxp3 Tregs Accumulate in Lung
Tumors
To measure the proportion of lymphocytes infiltrat-
ing tumors, we used flow cytometry. We found that the
proportion of total CD4 TIL among CD45 leukocytes in
the center of adenocarcinomas was significantly enhanced,
when compared with the tumor border (Figure 2, p 
0.02), whereas squamous cell carcinoma samples showed
only a nonsignificant difference between the different lung
tissue samples. There were no changes in total CD4
T-cell numbers between healthy lung samples and tumor-
infiltrated lung tissue. Similarly, we observed no differ-
ences between total CD8 T cell amounts among CD45
leukocytes in tumors and in adjacent healthy lung tissues
(data not shown).
We found a significantly enhanced proportion of
CD4CD25Foxp3 Tregs in the tumor center, when com-
pared with healthy lung tissue and the tumor border (Figure
3B; p  0.05 for both). Analyzing tumor samples of differ-
ent histology, we found that these differences held true for
adenocarcinoma (Figure 3C; p  0.01), whereas in squa-
mous cell carcinoma, a statistically significant increase
was found only in comparison with healthy lung tissue
(Figure 3D; p  0.002).
FIGURE 2. Analysis of CD4 T cells in lung tissue of patients with cancer. Single-cell suspensions prepared from healthy lung
tissues, tumor centers, and tumor borders were stained with monoclonal antibodies (mAbs) for CD4 and the leukocyte marker
CD45 followed by flow cytometry. A, Representative dot plots and gating strategy. B–D, Percentage of CD4 T cells within
CD45 leukocytes in the lung tissue of all patients (B; n  30) and of patients with adenocarcinoma (C; n  16) or squamous
cell carcinoma (D; n  14). *p  0.02, significant differences between the groups indicated with the lines.
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Interestingly, we found a strong decrease in
CD56CD3 NK cells within CD45 leukocytes in samples
from the tumor center, when compared with those from
healthy lung tissue and the tumor border (Figure 4B; p 
0.01). This result was found both to adenocarcinoma and
squamous cell carcinoma samples (Figures 4C, D).
Enrichment of Tregs in Metastatic Lymph
Nodes
Flow-cytometric analysis of lymph nodes obtained
from patients with adenocarcinoma revealed a significantly
enhanced proportion of CD4 T cells in metastatic, when
compared with tumor-free lymph nodes (Figure 5B; p 
0.01). In squamous cell carcinoma, the enhancement of
CD4 T cells in TIL was less striking and statistically not
significant (Figure 5C). There was no significant difference in
CD8 and NK cell numbers between metastatic and non-
metastatic lymph nodes (data not shown).
We found significant enhancement of Tregs in meta-
static lymph nodes from patients with adenocarcinoma (Fig-
ure 6B; p  0.01). Nevertheless, in the case of squamous cell
carcinoma, the difference between Tregs in metastatic and
nonmetastatic lymph nodes was not significant (Figure 6C).
Investigating TIL and tumor-free lymph nodes in dif-
ferent positions (local, N1 tumor draining versus distant
mediastinal, N2), we observed no significant difference in the
number of any studied T-cell subsets, including total CD4,
Foxp3 Tregs, CD8, and NK cells.
DISCUSSION
There is growing evidence that Tregs play a key role in
suppressing T-cell-mediated immunity in patients with can-
cer.6,7 The efficacy of cancer vaccination is enhanced in
several animal models by depleting Tregs, whereas an adop-
tive transfer of Tregs impairs tumor-specific immunity, re-
sulting in tumor progression.13,14 Increased proportions of
Tregs in tumor tissue have been reported in different tumor
types, including lung cancer.15–18 Our findings in tumor-
infiltrated lung tissue are in line with a previous report,
showing a significantly enhanced proportion of Tregs and
fewer NK cells in tumor tissue compared with lung tissue.9
Interestingly in our series, this difference was also observed
between the tumor center and the tumor border. This obser-
vation might be explained by an increased concentration of
chemokines attracting Treg to the tumor center.6,7 Impor-
tantly, the proportion of NK cells in the center of primary
tumors with enhanced Treg infiltration was significantly de-
creased, when compared with both the healthy tissue and the
tumor border. NK cells are considered to be of vital impor-
tance to protect from tumor development by their ability to
recognize and eliminate transformed cells without previous
priming.19 This elimination depends on the balance between
inhibitory and activating signals engaged by ligands ex-
pressed on tumor cells.20 Nevertheless, recent evidence has
suggested that Tregs may suppress NK cell effector func-
tions, thereby modulating the reactivity of innate immunity.21
In this study, we provided the first evidence of an accu-
mulation of Foxp3 Tregs in TIL in human NSCLC. In adeno-
FIGURE 3. Distribution of
CD4CD25Foxp3 regulatory T
cells (Tregs) in lung tissue. Cells
from healthy lung tissues, tumor
centers, and tumor borders were
stained with monoclonal antibodies
(mAbs) for CD45, CD4, CD25, and
FoxP3, followed by flow cytometry.
A, Representative dot plots and
gating strategy. B–D, Frequency of
CD4CD25FoxP3 Tregs in the
lung tissue of all patients (B; n 
30; *p  0.05) and of patients with
adenocarcinoma (C; n  16; *p 
0.01) or squamous cell carcinoma
(D; n  14; *p  0.002) expressed
as percentage within total
CD45CD4 T cells.
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carcinomas, the proportion of these cells was significantly en-
hanced in metastatic lymph nodes compared with lymph node
samples without tumor infiltration. Only a few studies have
focused on Tregs in tumor-draining lymph nodes in human
cancer up to now.22–24 Similar to our data, increased Treg
numbers in tumor-infiltrated draining lymph nodes were re-
ported from patients with gastric cancer.22 In metastatic mela-
noma lymph nodes, Tregs were shown to be a major component
of the immunosuppressive microenvironment,25 and recent find-
ings indicate that the immunologic status of sentinel lymph
nodes is inhibited before further metastases develop.26 In con-
trast to some other tumor types, a typical sentinel lymph node
cannot be delineated in lung cancer. Furthermore, the phenom-
enon of lymph node skipping in the development of lymph node
metastases is well known.27,28 For this reason, lymphoid tissue
samples were obtained in this study from the locations closest to
the tumor (subsegmental N1 position) and from the most distant
(N2) area that is reached by mediastinal lymph node dissection.
We found no difference in the studied T-cell subset numbers
between samples from local (N1) and mediastinal (N2) lymph
nodes. This result was also true when tumor-free N2 lymph
nodes obtained from N1-positive patients were compared with
those from N1-negative patients. Only tumor infiltration into the
lymph nodes resulted in Treg accumulation.
FIGURE 4. Phenotypic analysis of
CD56CD3 natural killer (NK)
cells in lung tissue. Cells isolated
from healthy lung tissues, tumor
centers, and tumor borders were
stained with monoclonal antibodies
(mAbs) for CD45, CD3, and CD56,
followed by FACS analysis. A, Repre-
sentative dot plots and gating strat-
egy. B–D, Amount of CD56CD3
NK cells in the lung tissue of all pa-
tients (B; n  30; *p  0.01) and of
patients with adenocarcinoma (C;
n  16; *p  0.005) or squamous
cell carcinoma (D; n  14; *p 
0.02) expressed as percentages of all
CD45 leukocytes.
FIGURE 5. Evaluation of CD4 T cells in lymph nodes from patients with lung cancer. Cell suspensions prepared from tu-
mor-infiltrated lymph nodes, and lymph nodes lacking tumor infiltration were stained with monoclonal antibodies (mAbs) for
CD3 and CD4, followed by flow cytometry. A–C, Percentage of CD3CD4 T cells within mononuclear cells (MNC) in lymph
nodes of all patients (A; n  30), of patients with adenocarcinoma (B; n  16), or squamous cell carcinoma (C; n  14). *p 
0.01, significant differences between indicated groups.
Schneider et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer436
The impact of histological subtypes of NSCLC on Treg
accumulation has not been reported up to now. Our findings
indicate that adenocarcinoma can create a more profound
immunosuppressive microenvironment than squamous cell
carcinoma. This observation needs to be confirmed by
subsequent studies. Interestingly, similar numbers of Tregs
have previously been found studying NSCLC and small
cell lung cancer samples.19 In NSCLC samples, a higher
expression of Foxp3 was reported to correlate with de-
creasing tumor diameter.29
A high density of tumor-infiltrating Tregs detected by
immunohistochemistry was reported to be associated with the
recurrence of resected NSCLC.30 To correlate numbers of
lymphocyte populations with survival was not aim of this
study as patient numbers are too small; such a trial using
multitissue array analysis is currently ongoing.
In summary, we found an enrichment of immunosup-
pressive Tregs in primary tumor and tumor-infiltrated lym-
phoid tissue specimens obtained from patients who received
curative surgery for NSCLC in comparison with healthy lung.
This observation was particularly enhanced in patients with
adenocarcinomas. Treg accumulation was correlated with
reduction in NK cell numbers in primary tumors. As NK cells
have been demonstrated to play a key role in the antitumor
resistance in lungs,19 its down-regulation associated with
Treg expansion in lung tumor tissue may contribute to im-
munosuppression and tumor progression in patients with lung
cancer. Therefore, specific Treg elimination or suppression of
their activity may be a therapeutic venue to develop more
effective strategies of lung cancer immunotherapy.
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